

Brian Olshansky, Fhrs

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5288424/publications.pdf>

Version: 2024-02-01

360
papers

18,848
citations

11639

70
h-index

13758

129
g-index

388
all docs

388
docs citations

388
times ranked

12972
citing authors

#	ARTICLE	IF	CITATIONS
1	Guidelines for the diagnosis and management of syncope (version 2009): The Task Force for the Diagnosis and Management of Syncope of the European Society of Cardiology (ESC). <i>European Heart Journal</i> , 2009, 30, 2631-2671.	1.0	1,784
2	Reduction in Inappropriate Therapy and Mortality through ICD Programming. <i>New England Journal of Medicine</i> , 2012, 367, 2275-2283.	13.9	1,186
3	2015 Heart Rhythm Society Expert Consensus Statement on the Diagnosis and Treatment of Postural Tachycardia Syndrome, Inappropriate Sinus Tachycardia, and Vasovagal Syncope. <i>Heart Rhythm</i> , 2015, 12, e41-e63.	0.3	694
4	Catheter Ablation of Accessory Pathways, Atrioventricular Nodal Reentrant Tachycardia, and the Atrioventricular Junction. <i>Circulation</i> , 1999, 99, 262-270.	1.6	591
5	Factors Affecting Quality of Anticoagulation Control Among Patients With Atrial Fibrillation on Warfarin. <i>Chest</i> , 2013, 144, 1555-1563.	0.4	440
6	The Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study. <i>Journal of the American College of Cardiology</i> , 2004, 43, 1201-1208.	1.2	378
7	Parasympathetic Nervous System and Heart Failure. <i>Circulation</i> , 2008, 118, 863-871.	1.6	377
8	Heart Failure and Sudden Death in Patients With Tachycardia-Induced Cardiomyopathy and Recurrent Tachycardia. <i>Circulation</i> , 2004, 110, 247-252.	1.6	326
9	2015 ACC/AHA/HRS Guideline for the Management of Adult Patients With Supraventricular Tachycardia. <i>Journal of the American College of Cardiology</i> , 2016, 67, e27-e115.	1.2	325
10	2015 ACC/AHA/HRS Guideline for the Management of Adult Patients With Supraventricular Tachycardia. <i>Circulation</i> , 2016, 133, e506-74.	1.6	320
11	Arrhythmia-Induced Cardiomyopathies. <i>Journal of the American College of Cardiology</i> , 2015, 66, 1714-1728.	1.2	277
12	Electrophysiological testing and nonsustained ventricular tachycardia. Use and limitations in patients with coronary artery disease and impaired ventricular function.. <i>Circulation</i> , 1990, 82, 350-358.	1.6	266
13	Demonstration of an area of slow conduction in atrial flutter. <i>Journal of the American College of Cardiology</i> , 1990, 16, 1639-1648.	1.2	240
14	2017 ACC/AHA/HRS Guideline for the Evaluation and Management of Patients With Syncope. <i>Journal of the American College of Cardiology</i> , 2017, 70, e39-e110.	1.2	231
15	A Practical Guide for Clinicians Who Treat Patients with Amiodarone: 2007. <i>Heart Rhythm</i> , 2007, 4, 1250-1259.	0.3	220
16	Analysis of Cause-Specific Mortality in the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Study. <i>Circulation</i> , 2004, 109, 1973-1980.	1.6	215
17	2017 ACC/AHA/HRS Guideline for the Evaluation and Management of Patients With Syncope: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. <i>Circulation</i> , 2017, 136, e25-e59.	1.6	215
18	Energy, current, and success in defibrillation and cardioversion: clinical studies using an automated impedance-based method of energy adjustment.. <i>Circulation</i> , 1988, 77, 1038-1046.	1.6	209

#	ARTICLE	IF	CITATIONS
19	Safety of Sports for Athletes With Implantable Cardioverter-Defibrillators. <i>Circulation</i> , 2013, 127, 2021-2030.	1.6	209
20	2017 ISHNE-HRS expert consensus statement on ambulatory ECG and external cardiac monitoring/telemetry. <i>Heart Rhythm</i> , 2017, 14, e55-e96.	0.3	204
21	Adenosine-sensitive ventricular tachycardia. Clinical characteristics and response to catheter ablation.. <i>Circulation</i> , 1993, 87, 126-134.	1.6	199
22	Guidance for cardiac electrophysiology during the COVID-19 pandemic from the Heart Rhythm Society COVID-19 Task Force; Electrophysiology Section of the American College of Cardiology; and the Electrocardiography and Arrhythmias Committee of the Council on Clinical Cardiology, American Heart Association. <i>Heart Rhythm</i> , 2020, 17, e233-e241.	0.3	190
23	2017 ACC/AHA/HRS Guideline for the Evaluation and Management of Patients With Syncope: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. <i>Circulation</i> , 2017, 136, e60-e122.	1.6	189
24	Demonstration of the presence of slow conduction during sustained ventricular tachycardia in man: use of transient entrainment of the tachycardia.. <i>Circulation</i> , 1987, 75, 369-378.	1.6	179
25	Practical Guidelines for Clinicians Who Treat Patients With Amiodarone. <i>Archives of Internal Medicine</i> , 2000, 160, 1741.	4.3	178
26	Reduction in Ventricular Tachyarrhythmias With Statins in the Multicenter Automatic Defibrillator Implantation Trial (MADIT)-II. <i>Journal of the American College of Cardiology</i> , 2006, 47, 769-773.	1.2	169
27	2017 ACC/AHA/HRS guideline for the evaluation and management of patients with syncope. <i>Heart Rhythm</i> , 2017, 14, e155-e217.	0.3	163
28	Is Dual-Chamber Programming Inferior to Single-Chamber Programming in an Implantable Cardioverter-Defibrillator?. <i>Circulation</i> , 2007, 115, 9-16.	1.6	159
29	Baseline characteristics of patients with atrial fibrillation: The AFFIRM Study. <i>American Heart Journal</i> , 2002, 143, 991-1001.	1.2	157
30	Characterization of double potentials in human atrial flutter: Studies during transient entrainment. <i>Journal of the American College of Cardiology</i> , 1990, 15, 833-841.	1.2	147
31	Are Transthoracic Echocardiographic Parameters Associated With Atrial Fibrillation Recurrence or Stroke?. <i>Journal of the American College of Cardiology</i> , 2005, 45, 2026-2033.	1.2	142
32	Does intensity of rate-control influence outcome in atrial fibrillation? An analysis of pooled data from the RACE and AFFIRM studies. <i>Europace</i> , 2006, 8, 935-942.	0.7	141
33	Long-Haul Post-“COVID-19 Symptoms Presenting as a Variant of Postural Orthostatic Tachycardia Syndrome. <i>JACC: Case Reports</i> , 2021, 3, 573-580.	0.3	141
34	Rate control in atrial fibrillation. <i>Lancet, The</i> , 2016, 388, 818-828.	6.3	140
35	A fourth criterion for transient entrainment: the electrogram equivalent of progressive fusion.. <i>Circulation</i> , 1988, 77, 1003-1012.	1.6	137
36	Inappropriate Sinus Tachycardia. <i>Journal of the American College of Cardiology</i> , 2013, 61, 793-801.	1.2	135

#	ARTICLE	IF	CITATIONS
37	2017 ACC/AHA/HRS Guideline for the Evaluation and Management of Patients With Syncope: Executive Summary. Journal of the American College of Cardiology, 2017, 70, 620-663.	1.2	131
38	Influence of Left Ventricular Lead Location on Outcomes in the COMPANION Study. Journal of Cardiovascular Electrophysiology, 2009, 20, 764-768.	0.8	129
39	Improved Outcomes by Integrated Care of Anticoagulated Patients with Atrial Fibrillation Using the Simple ABC (Atrial Fibrillation Better Care) Pathway. American Journal of Medicine, 2018, 131, 1359-1366.e6.	0.6	129
40	Integrating Complementary Medicine Into Cardiovascular Medicine. Journal of the American College of Cardiology, 2005, 46, 184-221.	1.2	126
41	Significance of inducible tachycardia in patients with syncope of unknown origin: A long-term follow-up. Journal of the American College of Cardiology, 1985, 5, 216-223.	1.2	125
42	Guidance for Cardiac Electrophysiology During the COVID-19 Pandemic from the Heart Rhythm Society COVID-19 Task Force; Electrophysiology Section of the American College of Cardiology; and the Electrocardiography and Arrhythmias Committee of the Council on Clinical Cardiology, American Heart Association. Circulation, 2020, 141, e823-e831.	1.6	122
43	Bolus isoproterenol infusions provide a reliable method for assessing interoceptive awareness. International Journal of Psychophysiology, 2009, 72, 34-45.	0.5	120
44	Safety of Sports Participation in Patients with Implantable Cardioverter Defibrillators: A Survey of Heart Rhythm Society Members. Journal of Cardiovascular Electrophysiology, 2006, 17, 11-15.	0.8	111
45	document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology Working Group on Thrombosis, endorsed by the ESC Working Group on Valvular Heart Disease, Cardiac Arrhythmia Society of Southern Africa (CASSA), Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), South African Heart (SA Heart) Association and Sociedad Latinoamericana de Estimulaci3n Cardíaca y Europace, 2017, 19, 1757-1758.	0.7	107
46	Safety of Sports for Athletes With Implantable Cardioverter-Defibrillators. Circulation, 2017, 135, 2310-2312.	1.6	107
47	Syncope Predicts the Outcome of Cardiomyopathy Patients. Journal of the American College of Cardiology, 2008, 51, 1277-1282.	1.2	106
48	REDUCE-IT USA. Circulation, 2020, 141, 367-375.	1.6	104
49	Patterns and Predictors of Warfarin Use in Patients With New-Onset Atrial Fibrillation from the FRACTAL Registry. American Journal of Cardiology, 2006, 97, 538-543.	0.7	102
50	Mortality Reduction in Relation to Implantable Cardioverter Defibrillator Programming in the Multicenter Automatic Defibrillator Implantation Trial-Reduce Inappropriate Therapy (MADIT-RIT). Circulation: Arrhythmia and Electrophysiology, 2014, 7, 785-792.	2.1	101
51	N-Acetyl procainamide causing torsades de pointes. American Journal of Cardiology, 1982, 50, 1439-1441.	0.7	99
52	PR Interval Identifies Clinical Response in Patients With Non-Left Bundle Branch Block. Circulation: Arrhythmia and Electrophysiology, 2014, 7, 645-651.	2.1	98
53	Syncope Unit: rationale and requirement – the European Heart Rhythm Association position statement endorsed by the Heart Rhythm Society. Europace, 2015, 17, 1325-1340.	0.7	98
54	Thromboembolism in Chronic Atrial Flutter: Is the Risk Underestimated?. Journal of the American College of Cardiology, 1997, 30, 1506-1511.	1.2	97

#	ARTICLE	IF	CITATIONS
55	2015 ACC/AHA/HRS Guideline for the Management of Adult Patients With Supraventricular Tachycardia: Executive Summary. <i>Circulation</i> , 2016, 133, e471-505.	1.6	96
56	Syncope clinical management in the emergency department: a consensus from the first international workshop on syncope risk stratification in the emergency department. <i>European Heart Journal</i> , 2016, 37, 1493-1498.	1.0	96
57	Management of Atrial Fibrillation After Coronary Artery Bypass Graft. <i>American Journal of Cardiology</i> , 1996, 78, 27-34.	0.7	94
58	Report of the NASPE Policy Conference on Arrhythmias and the Athlete. <i>Journal of Cardiovascular Electrophysiology</i> , 2001, 12, 1208-1219.	0.8	94
59	Practical Management Guide for Clinicians Who Treat Patients with Amiodarone. <i>American Journal of Medicine</i> , 2016, 129, 468-475.	0.6	86
60	2015 ACC/AHA/HRS Guideline for the Management of Adult Patients With Supraventricular Tachycardia: Executive Summary. <i>Journal of the American College of Cardiology</i> , 2016, 67, 1575-1623.	1.2	86
61	Relation of Gender-Specific Risk of Ischemic Stroke in Patients With Atrial Fibrillation to Differences in Warfarin Anticoagulation Control (from AFFIRM). <i>American Journal of Cardiology</i> , 2012, 110, 1799-1802.	0.7	85
62	2015 ACC/AHA/HRS guideline for the management of adult patients with supraventricular tachycardia. <i>Heart Rhythm</i> , 2016, 13, e136-e221.	0.3	84
63	Comprehensive Management With the ABC (Atrial Fibrillation Better Care) Pathway in Clinically Complex Patients With Atrial Fibrillation: A Post Hoc Ancillary Analysis From the AFFIRM Trial. <i>Journal of the American Heart Association</i> , 2020, 9, e014932.	1.6	84
64	Statin use was associated with reduced mortality in both ischemic and nonischemic cardiomyopathy and in patients with implantable defibrillators: Mortality data and mechanistic insights from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT). <i>American Heart Journal</i> , 2007, 153, 573-578.	1.2	81
65	Interrelationships Between the Autonomic Nervous System and Atrial Fibrillation. <i>Progress in Cardiovascular Diseases</i> , 2005, 48, 57-78.	1.6	80
66	Priorities for Emergency Department Syncope Research. <i>Annals of Emergency Medicine</i> , 2014, 64, 649-655.e2.	0.3	79
67	Polypharmacy and major adverse events in atrial fibrillation: observations from the AFFIRM trial. <i>Clinical Research in Cardiology</i> , 2016, 105, 412-420.	1.5	78
68	Environmental and Drug Effects on Patients With Pacemakers and Implantable Cardioverter/Defibrillators. <i>Archives of Internal Medicine</i> , 2001, 161, 649.	4.3	76
69	Placebo and Nocebo in Cardiovascular Health. <i>Journal of the American College of Cardiology</i> , 2007, 49, 415-421.	1.2	76
70	Clinical significance of syncope in the Electrophysiologic Study Versus Electrocardiographic Monitoring (ESVEM) trial. <i>American Heart Journal</i> , 1999, 137, 878-886.	1.2	73
71	Outpatient cardioversion of atrial arrhythmias: Efficacy, safety, and costs. <i>American Heart Journal</i> , 2003, 145, 233-238.	1.2	73
72	Cardiac implantable electronic device infections: Who is at greatest risk?. <i>Heart Rhythm</i> , 2017, 14, 839-845.	0.3	70

#	ARTICLE	IF	CITATIONS
73	Variation of left ventricular myocardial gray level on two-dimensional echocardiograms as a result of cardiac contraction.. Circulation, 1984, 70, 972-977.	1.6	69
74	Mineral oil: safety and use as placebo in REDUCE-IT and other clinical studies. European Heart Journal Supplements, 2020, 22, J34-J48.	0.0	68
75	Effectiveness of radiofrequency catheter ablation for treatment of atrial tachycardia. American Journal of Cardiology, 1993, 72, 787-793.	0.7	64
76	Newly detected atrial fibrillation in patients with an implantable cardioverter-defibrillator is a strong risk marker of increased mortality. Heart Rhythm, 2009, 6, 2-8.	0.3	64
77	Differential Pharmacological Effects of Antimuscarinic Drugs on Heart Rate: A Randomized, Placebo-controlled, Double-blind, Crossover Study With Tolterodine and Darifenacin in Healthy Participants â€”50 Years. Journal of Cardiovascular Pharmacology and Therapeutics, 2008, 13, 241-251.	1.0	63
78	Does cardiac resynchronization therapy provide unrecognized benefit in patients with prolonged PR intervals? The impact of restoring atrioventricular synchrony: An analysis from the COMPANION Trial. Heart Rhythm, 2012, 9, 34-39.	0.3	63
79	HRS/ACCF Expert Consensus Statement on Pacemaker Device and Mode Selection. Journal of the American College of Cardiology, 2012, 60, 682-703.	1.2	62
80	European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS) expert consensus on risk assessment in cardiac arrhythmias: use the right tool for the right outcome, in the right population. Europace, 2020, 22, 1147-1148.	0.7	62
81	Use of procainamide with rapid atrial pacing for successful conversion of atrial flutter to sinus rhythm. Journal of the American College of Cardiology, 1988, 11, 359-364.	1.2	60
82	HRS/ACCF Expert Consensus Statement on Pacemaker Device and Mode Selection. Heart Rhythm, 2012, 9, 1344-1365.	0.3	60
83	Postural Orthostatic Tachycardia Syndrome (POTS): A critical assessment. Progress in Cardiovascular Diseases, 2020, 63, 263-270.	1.6	58
84	Heart Rate Predicts Outcomes in an Implantable Cardioverter-Defibrillator Population. Circulation, 2009, 120, 2040-2045.	1.6	57
85	Cardiac effects of muscarinic receptor antagonists used for voiding dysfunction. British Journal of Clinical Pharmacology, 2011, 72, 186-196.	1.1	56
86	Ventricular tachycardia rate and morphology determine energy and current requirements for transthoracic cardioversion.. Circulation, 1992, 85, 158-163.	1.6	55
87	Inflammatory cytokines and nitric oxide in heart failure and potential modulation by vagus nerve stimulation. Heart Failure Reviews, 2011, 16, 137-145.	1.7	54
88	A Randomized, Placeboâ€”Controlled Trial of Omegaâ€”3 Fatty Acids for Inhibition of Supraventricular Arrhythmias After Cardiac Surgery: The FISH Trial. Journal of the American Heart Association, 2012, 1, e000547.	1.6	54
89	Managing Atrial Fibrillation in Patients With Heart Failure and Reduced Ejection Fraction: A Scientific Statement From the American Heart Association. Circulation: Arrhythmia and Electrophysiology, 2021, 14, HAE0000000000000078.	2.1	54
90	Meta-Analysis of the Relation of Ventricular Arrhythmias to All-Cause Mortality After Implantation of a Left Ventricular Assist Device. American Journal of Cardiology, 2015, 116, 1385-1390.	0.7	52

#	ARTICLE	IF	CITATIONS
91	2017 ISHNE-HRS expert consensus statement on ambulatory ECG and external cardiac monitoring/telemetry. , 2017, 22, e12447.		52
92	Inappropriate sinus tachycardia. <i>Europace</i> , 2019, 21, 194-207.	0.7	50
93	Tilt testing remains a valuable asset. <i>European Heart Journal</i> , 2021, 42, 1654-1660.	1.0	50
94	Atrial Flutter-Update on the Mechanism and Treatment. <i>PACE - Pacing and Clinical Electrophysiology</i> , 1992, 15, 2308-2335.	0.5	49
95	Etiologic Considerations in the Patient With Syncope and an Apparently Normal Heart. <i>Archives of Internal Medicine</i> , 2003, 163, 151.	4.3	47
96	Recognition, Prevention, and Management of Arrhythmias and Autonomic Disorders in Cardio-Oncology: A Scientific Statement From the American Heart Association. <i>Circulation</i> , 2021, 144, e41-e55.	1.6	47
97	Electrocardiographic body surface potential mapping in the Wolff-Parkinson-White syndrome. Noninvasive determination of the ventricular insertion sites of accessory atrioventricular connections.. <i>Circulation</i> , 1991, 83, 886-901.	1.6	46
98	Relation of female sex to left atrial diameter and cardiovascular death in atrial fibrillation: The AFFIRM Trial. <i>International Journal of Cardiology</i> , 2016, 207, 258-263.	0.8	43
99	Long-Term Outcomes of Implantable Cardioverter-Defibrillator Therapy in the ASCD-HeFT. <i>Journal of the American College of Cardiology</i> , 2020, 76, 405-415.	1.2	43
100	Ambulatory ECG Monitoring in Atrial Fibrillation Management. <i>Progress in Cardiovascular Diseases</i> , 2013, 56, 143-152.	1.6	41
101	Sports and Exercise Cardiology in the United States. <i>Journal of the American College of Cardiology</i> , 2014, 63, 1461-1472.	1.2	41
102	Antithrombotic Therapy in Atrial Fibrillation Associated with Valvular Heart Disease: Executive Summary of a Joint Consensus Document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology Working Group on Thrombosis, Endorsed by the ESC Working Group on Valvular Heart Disease, Cardiac Arrhythmia Society of Southern Africa (CASSA), Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), South African Heart (SA Heart) Association and Sociedad Latinoamericana de Es. Thrombosis and Haemostasis, 2017, 117, 2215-2236.	1.8	41
103	Eliminating right ventricular pacing may not be best for patients requiring implantable cardioverter-defibrillators. <i>Heart Rhythm</i> , 2007, 4, 886-891.	0.3	40
104	European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS) expert consensus on risk assessment in cardiac arrhythmias: use the right tool for the right outcome, in the right population. <i>Journal of Arrhythmia</i> , 2020, 36, 553-607.	0.5	40
105	Use of amiodarone for atrial fibrillation in patients with preexisting pulmonary disease in the AFFIRM study. <i>American Journal of Cardiology</i> , 2005, 95, 404-405.	0.7	39
106	Safety of Sports for Young Patients With Implantable Cardioverter-Defibrillators. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2018, 11, e006305.	2.1	39
107	Tachycardia-mediated cardiomyopathy: Recognition and management. <i>Current Heart Failure Reports</i> , 2009, 6, 257-264.	1.3	37
108	Multicenter Automatic Defibrillator Implantation Trial: Reduce Inappropriate Therapy (MADIT-Â€RIT): Background, Rationale, and Clinical Protocol. <i>Annals of Noninvasive Electrocardiology</i> , 2012, 17, 176-185.	0.5	36

#	ARTICLE	IF	CITATIONS
109	Left ventricular geometry and outcomes in patients with atrial fibrillation: The AFFIRM Trial. <i>International Journal of Cardiology</i> , 2014, 170, 303-308.	0.8	36
110	Vagus nerve modulation of inflammation: Cardiovascular implications. <i>Trends in Cardiovascular Medicine</i> , 2016, 26, 1-11.	2.3	36
111	Are treatments for vasovagal syncope effective? A meta-analysis. <i>International Journal of Cardiology</i> , 2013, 167, 1906-1911.	0.8	35
112	Variation in the utilization of antiarrhythmic drugs in patients with new-onset atrial fibrillation. <i>American Journal of Cardiology</i> , 2003, 91, 81-83.	0.7	34
113	Adenosine-Sensitive Atrial Tachycardia. <i>PACE - Pacing and Clinical Electrophysiology</i> , 1995, 18, 300-306.	0.5	33
114	Reduction of Right Ventricular Pacing in Patients with Dual-Chamber ICDs. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2006, 29, 237-243.	0.5	33
115	Sex Differences in the Relationship Between Amiodarone Use and the Need for Permanent Pacing in Patients With Atrial Fibrillation. <i>Archives of Internal Medicine</i> , 2007, 167, 1648.	4.3	33
116	APOPTOSIS IN THE GENESIS OF CARDIAC RHYTHM DISORDERS. <i>Cardiology Clinics</i> , 2001, 19, 155-163.	0.9	32
117	Intensive recreational athletes in the prospective multinational ICD Sports Safety Registry: Results from the European cohort. <i>European Journal of Preventive Cardiology</i> , 2019, 26, 764-775.	0.8	32
118	Inhibition of Unnecessary RV Pacing with AV Search Hysteresis in ICDs (INTRINSIC RV):. Design and Clinical Protocol. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2005, 28, 62-66.	0.5	31
119	Arrhythmias in tako-tsubo syndrome—Benign or malignant?. <i>International Journal of Cardiology</i> , 2007, 114, 141-144.	0.8	31
120	Implantable Cardioverter Defibrillators: Do Women Fare Worse Than Men? Gender Comparison in the INTRINSIC RV Trial. <i>Journal of Cardiovascular Electrophysiology</i> , 2009, 20, 973-978.	0.8	31
121	Usefulness of isoproterenol facilitation of ventricular tachycardia induction during extrastimulus testing in predicting effective chronic therapy with beta-adrenergic blockade. <i>American Journal of Cardiology</i> , 1987, 59, 573-577.	0.7	30
122	Do implantable cardioverter defibrillators improve survival in patients with chronic kidney disease at high risk of sudden cardiac death? A meta-analysis of observational studies. <i>Europace</i> , 2014, 16, 55-62.	0.7	30
123	Usefulness of isoproterenol in facilitating atrioventricular nodal reentry tachycardia during electrophysiologic testing. <i>American Journal of Cardiology</i> , 1988, 61, 1037-1041.	0.7	29
124	High defibrillation energy requirements are encountered rarely with modern dual-chamber implantable cardioverter-defibrillator systems. <i>Europace</i> , 2008, 10, 347-350.	0.7	28
125	Systolic Blood Pressure Visit-to-Visit Variability and Major Adverse Outcomes in Atrial Fibrillation. <i>Hypertension</i> , 2017, 70, 949-958.	1.3	28
126	Characterization of double potentials during ventricular tachycardia. Studies during transient entrainment.. <i>Circulation</i> , 1993, 87, 373-381.	1.6	27

#	ARTICLE	IF	CITATIONS
127	A Pepsi Challenge. <i>New England Journal of Medicine</i> , 1999, 340, 2006-2006.	13.9	27
128	Where patients with mild to moderate heart failure die: Results from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT). <i>American Heart Journal</i> , 2007, 153, 1089-1094.	1.2	27
129	Treating patients with overactive bladder syndrome with antimuscarinics: heart rate considerations. <i>BJU International</i> , 2007, 100, 1007-1014.	1.3	27
130	Correlation of Noninvasive Electrocardiography with Invasive Electrophysiology in Syncope of Unknown Origin: Implications from a Large Syncope Database. <i>Annals of Noninvasive Electrocardiology</i> , 2009, 14, 119-127.	0.5	27
131	2017 ACC/AHA/HRS guideline for the evaluation and management of patients with syncope: Executive summary. <i>Heart Rhythm</i> , 2017, 14, e218-e254.	0.3	27
132	Competitive athletes with implantable cardioverter-defibrillators—How to program? Data from the Implantable Cardioverter-Defibrillator Sports Registry. <i>Heart Rhythm</i> , 2019, 16, 581-587.	0.3	27
133	Management of tachycardia. <i>F1000prime Reports</i> , 2015, 7, 60.	5.9	26
134	Predictors of Defibrillation Energy Requirements with Nonpicardial Lead Systems. <i>PACE - Pacing and Clinical Electrophysiology</i> , 1995, 18, 253-260.	0.5	25
135	Influence of Diabetes Mellitus on Inappropriate and Appropriate Implantable Cardioverter-Defibrillator Therapy and Mortality in the Multicenter Automatic Defibrillator Implantation Trial—Reduce Inappropriate Therapy (MADIT-RIT) Trial. <i>Circulation</i> , 2013, 128, 694-701.	1.6	25
136	Orthostatic Hypotension: Management of a Complex, But Common, Medical Problem. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2022, 15, CIRCEP121010573.	2.1	25
137	The Clinical Significance of Nonsustained Ventricular Tachycardia: Current Perspectives. <i>PACE - Pacing and Clinical Electrophysiology</i> , 1994, 17, 637-664.	0.5	24
138	Syncope: Outcomes and Conditions Associated with Hospitalization. <i>American Journal of Medicine</i> , 2017, 130, 699-706.e6.	0.6	24
139	Quantitative Echocardiographic Image Texture: Normal Contraction-Related Variability. <i>IEEE Transactions on Medical Imaging</i> , 1985, 4, 185-192.	5.4	23
140	Survival After Rate-Responsive Programming in Patients With Cardiac Resynchronization Therapy-Defibrillator Implants Is Associated With a Novel Parameter. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2016, 9, .	2.1	23
141	2015 ACC/AHA/HRS guideline for the management of adult patients with supraventricular tachycardia: Executive summary. <i>Heart Rhythm</i> , 2016, 13, e92-e135.	0.3	23
142	REDUCE-IT INTERIM: accumulation of data across prespecified interim analyses to final results. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021, 7, e61-e63.	1.4	23
143	Stimulant Drugs of Abuse and Cardiac Arrhythmias. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2022, 15, CIRCEP121010273.	2.1	23
144	The SAME-TT2R2 score and quality of anticoagulation in AF: Can we predict which patient benefits from anticoagulation?. <i>Thrombosis and Haemostasis</i> , 2015, 114, 657-659.	1.8	22

#	ARTICLE	IF	CITATIONS
145	Longitudinal changes in quality of life following ICD implant and the impact of age, gender, and ICD shocks: observations from the INTRINSIC RV trial. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2017, 48, 291-298.	0.6	22
146	Pacing for Vasovagal Syncope. <i>Arrhythmia and Electrophysiology Review</i> , 2018, 7, 95.	1.3	22
147	Scatter Diagram Analysis: A New Technique for Discriminating Ventricular Tachyarrhythmias. <i>PACE - Pacing and Clinical Electrophysiology</i> , 1994, 17, 1267-1275.	0.5	21
148	Mortality After Atrioventricular Nodal Radiofrequency Catheter Ablation With Permanent Ventricular Pacing in Atrial Fibrillation. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2016, 9, .	2.1	21
149	The Impact of Atrial Prevention and Termination Therapies on Atrial Tachyarrhythmia Burden in Patients Receiving a Dual-Chamber Defibrillator for Ventricular Arrhythmias. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2004, 10, 103-110.	0.6	20
150	Arrhythmia rate distribution and tachyarrhythmia therapy in an ICD population: Results from the INTRINSIC RV trial. <i>Heart Rhythm</i> , 2012, 9, 351-358.	0.3	20
151	Mast Cell Activation Disorder and Postural Orthostatic Tachycardia Syndrome: A Clinical Association. <i>Journal of the American Heart Association</i> , 2021, 10, e021002.	1.6	20
152	Ventricular tachycardia masquerading as supraventricular tachycardia: A wolf in sheep's clothing. <i>Journal of Electrocardiology</i> , 1988, 21, 377-384.	0.4	19
153	Addendum to the clinical competency statement: training pathways for implantation of cardioverter defibrillators and cardiac resynchronization devices. <i>Heart Rhythm</i> , 2005, 2, 1161-1163.	0.3	19
154	Strokeâ€prevention strategies in North American patients with atrial fibrillation: The GLORIAâ€AF registry program. <i>Clinical Cardiology</i> , 2018, 41, 744-751.	0.7	19
155	Dabigatran Persistence and Outcomes Following Discontinuation in Atrial Fibrillation Patients from the GLORIA-AF Registry. <i>American Journal of Cardiology</i> , 2020, 125, 383-391.	0.7	19
156	Delayed maximal response to left cardiac sympathectomy for catecholaminergic polymorphic ventricular tachycardia. <i>Europace</i> , 2010, 12, 1035-1039.	0.7	18
157	Peripheral Arterial Disease in Patients with Atrial Fibrillation: The AFFIRM Study. <i>American Journal of Medicine</i> , 2021, 134, 514-518.	0.6	18
158	Early versus late atrial fibrillation after atrial flutter ablation. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2002, 6, 173-180.	0.6	17
159	Hormone Replacement Therapy and Adverse Outcomes in Women With Atrial Fibrillation. <i>Stroke</i> , 2014, 45, 3076-3079.	1.0	17
160	On the Underutilization of Cardiac Resynchronization Therapy. <i>Journal of Cardiac Failure</i> , 2014, 20, 696-705.	0.7	17
161	Digoxin Use to Control Ventricular Rate in Patients with Atrial Fibrillation and Heart Failure Is Not Associated with Increased Mortality. <i>Cardiology Research and Practice</i> , 2015, 2015, 1-10.	0.5	17
162	Significance and Incidence of Concordance of Drug Efficacy Predictions by Holter Monitoring and Electrophysiological Study in the ESVEM Trial. <i>Circulation</i> , 1995, 91, 1988-1995.	1.6	17

#	ARTICLE	IF	CITATIONS
163	Importance of resting heart rate. Trends in Cardiovascular Medicine, 2023, 33, 502-515.	2.3	17
164	Control of Refractory Ventricular Tachycardia with Biventricular Assist Devices. PACE - Pacing and Clinical Electrophysiology, 1991, 14, 1432-1434.	0.5	16
165	Atrial Tachycardia Originating from a Single Site with Exit Block Mimicking Atrial Fibrillation Eliminated with Radiofrequency Applications. Journal of Cardiovascular Electrophysiology, 1998, 9, 1100-1108.	0.8	16
166	Ventricular tachycardia with QRS configuration similar to that in sinus rhythm and a myocardial origin: differential diagnosis with bundle branch reentry. Europace, 2001, 3, 115-123.	0.7	16
167	The C-CURE Randomized Clinical Trial (Cardiopoeitic stem Cell therapy in heart failURE). Journal of the American College of Cardiology, 2013, 62, 2453.	1.2	16
168	Time-dependent risk reduction of ventricular tachyarrhythmias in cardiac resynchronization therapy patients: a MADIT-RIT sub-study. Europace, 2015, 17, 1085.1-1091.	0.7	16
169	A Device Histogram-Based Simple Predictor of Mortality Risk in ICD and CRT Patients: The Heart Rate Score. PACE - Pacing and Clinical Electrophysiology, 2017, 40, 333-343.	0.5	16
170	Current-based transthoracic defibrillation. American Journal of Cardiology, 1996, 78, 1113-1118.	0.7	15
171	Is Syncope the Same Thing as Sudden Death Except that You Wake Up?. Journal of Cardiovascular Electrophysiology, 1997, 8, 1098-1101.	0.8	15
172	Irregular Atrial Activation During Atrioventricular Nodal Reentrant Tachycardia:. Journal of Cardiovascular Electrophysiology, 2003, 14, 309-313.	0.8	15
173	Effect of Ablation for Atrial Fibrillation on Heart Failure Readmission Rates. American Journal of Cardiology, 2017, 120, 1572-1577.	0.7	15
174	European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS) expert consensus on risk assessment in cardiac arrhythmias: use the right tool for the right outcome, in the right population. Heart Rhythm, 2020, 17, e269-e316.	0.3	15
175	Cardiovascular Safety Considerations in the Treatment of Neurogenic Orthostatic Hypotension. American Journal of Cardiology, 2020, 125, 1582-1593.	0.7	15
176	The Dual Role of Implantable Loop Recorder in Patients with Potentially Arrhythmic Symptoms: A Retrospective Single-Center Study. PACE - Pacing and Clinical Electrophysiology, 2009, 32, 908-912.	0.5	14
177	Syncope: Overview and Approach to Management. , 0, , 1-46.		14
178	Apparent Failure of a Precordial Magnet and Pacemaker Programmer to Convert a DDD Pacemaker to VOO Mode during the Use of the Electrosurgical Unit. Anesthesiology, 1997, 86, 247-250.	1.3	13
179	Retroactive prayer: a preposterous hypothesis?. BMJ: British Medical Journal, 2003, 327, 1465-1468.	2.4	13
180	Drug Interactions Affecting Oral Anticoagulant Use. Circulation: Arrhythmia and Electrophysiology, 2022, 15, .	2.1	13

#	ARTICLE	IF	CITATIONS
181	Nonsustained ventricular tachycardia and other high-risk predictors following myocardial infarction: Implications for prophylactic automatic implantable cardioverter-defibrillator use. <i>Progress in Cardiovascular Diseases</i> , 1993, 36, 179-194.	1.6	12
182	Influence of holter monitor and electrophysiologic study methods and efficacy criteria on the outcome of patients with ventricular tachycardia and ventricular fibrillation in the ESVEM trial. <i>Progress in Cardiovascular Diseases</i> , 1996, 38, 359-370.	1.6	12
183	Implantable Defibrillator Use for De Novo Ventricular Tachyarrhythmias Encountered After Cardiac Surgery. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2002, 25, 951-956.	0.5	12
184	Increased Prevalence of Atrial Fibrillation in the Endurance Athlete: Potential Mechanisms and Sport Specificity. <i>Physician and Sportsmedicine</i> , 2014, 42, 45-51.	1.0	12
185	Predictors of myocardial recovery in arrhythmia-induced cardiomyopathy: A multicenter study. <i>Journal of Cardiovascular Electrophysiology</i> , 2021, 32, 1085-1092.	0.8	12
186	Global Oral Anticoagulation Use Varies by Region in Patients With Recent Diagnosis of Atrial Fibrillation: The GLORIA-AF Phase III Registry. <i>Journal of the American Heart Association</i> , 2022, 11, e023907.	1.6	12
187	Use of multiple patches during implantation of epicardial defibrillator systems. <i>American Journal of Cardiology</i> , 1993, 71, 68-71.	0.7	11
188	Cardiac Resynchronization Therapy May Be Antiarrhythmic Particularly in Responders. <i>JACC: Clinical Electrophysiology</i> , 2016, 2, 307-316.	1.3	11
189	The effect of cardiac resynchronization without a defibrillator on morbidity and mortality: an individual patient data meta-analysis of COMPANION and CARE-HF. <i>European Journal of Heart Failure</i> , 2022, 24, 1080-1090.	2.9	11
190	Nonthoracotomy lead system for implantable defibrillator. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 1993, 106, 1040-1047.	0.4	10
191	Syncope Evaluation at a Crossroad. <i>Circulation</i> , 2001, 104, 7-8.	1.6	10
192	Characterization and predictors of first and subsequent inappropriate ICD therapy by heart rate ranges: Result of the MADIT-RIT efficacy analysis. <i>Heart Rhythm</i> , 2015, 12, 2030-2037.	0.3	10
193	Atrial electrograms improve the accuracy of tachycardia interpretation from ICD and pacemaker recordings: The RATE Registry. <i>Heart Rhythm</i> , 2016, 13, 1475-1480.	0.3	10
194	Cardiac arrhythmias and the athlete. <i>Current Opinion in Cardiology</i> , 1999, 14, 24.	0.8	10
195	Cardiac Tamponade Caused by Pulmonary Artery Perforation after Central Venous Catheterization. <i>Journal of Parenteral and Enteral Nutrition</i> , 1984, 8, 711-713.	1.3	9
196	Slower Heart Rates for Healthy Hearts. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2008, 1, 321-323.	2.1	9
197	Update on medical management of atrial fibrillation in the modern era. <i>Heart Rhythm</i> , 2009, 6, S17-S22.	0.3	9
198	Omega-3 Fatty Acids Effect on Major Cardiovascular Events in Patients at High Cardiovascular Risk. <i>JAMA - Journal of the American Medical Association</i> , 2021, 325, 1332.	3.8	9

#	ARTICLE	IF	CITATIONS
199	Use of Implanted Antitachycardia Pacemakers to Treat Paroxysmal Atrial Flutter. <i>Annals of Internal Medicine</i> , 1987, 107, 247.	2.0	8
200	Electrophysiological Characterization of Cardiac Veins in Humans. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2004, 10, 241-247.	0.6	8
201	What's So Inappropriate About Sinus Tachycardia?. <i>Journal of Cardiovascular Electrophysiology</i> , 2008, 19, 977-978.	0.8	8
202	Does cardiac resynchronization therapy benefit patients with ischemic and non-ischemic cardiomyopathy similarly?. <i>International Journal of Cardiology</i> , 2013, 168, 4378-4380.	0.8	8
203	Heart rate score, a measure related to chronotropic incompetence in pacemaker patients. <i>Heart Rhythm O2</i> , 2021, 2, 124-131.	0.6	8
204	Location of death (in-hospital or out-of-hospital) and type of death (arrhythmic, nonarrhythmic,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 5. ventricular tachycardia, or nonfatal cardiac arrest (the ESVEM trial). <i>American Journal of Cardiology</i> , 2000, 86, 846-851.	0.7	7
205	Patient-Heal Thyself? Electrophysiology Meets Alternative Medicine. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2001, 24, 403-405.	0.5	7
206	Temporary biventricular pacing in a patient with subacute myocardial infarction, cardiogenic shock, and third-degree atrioventricular block. <i>Heart Rhythm</i> , 2005, 2, 112.	0.3	7
207	Task Force 9: Drugs and performance-enhancing substances. <i>Journal of the American College of Cardiology</i> , 2005, 45, 1368-1369.	1.2	7
208	Do Baseline Diastolic Echocardiographic Parameters Predict Outcome after Resynchronization Therapy? Results from the PROSPECT Trial. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2013, 36, 214-220.	0.5	7
209	Underlying hemodynamic differences are associated with responses to tilt testing. <i>Scientific Reports</i> , 2021, 11, 17894.	1.6	7
210	Autoregressive modeling of epicardial electrograms during ventricular fibrillation. <i>IEEE Transactions on Biomedical Engineering</i> , 1993, 40, 379-386.	2.5	6
211	Telectronics 330-801 Atrial Lead Extraction via the Subclavian Approach. <i>Annals of Thoracic Surgery</i> , 1997, 64, 175-180.	0.7	6
212	Vasovagal Syncope. <i>Journal of the American College of Cardiology</i> , 2017, 70, 1729-1731.	1.2	6
213	Addition of minute ventilation to rate-response pacing improves heart rate score more than accelerometer alone. <i>Heart Rhythm</i> , 2018, 15, 1730-1735.	0.3	6
214	Neurohormones in Vasovagal Syncope: Are They Important?. <i>Journal of the American Heart Association</i> , 2019, 8, e013129.	1.6	6
215	Drug Interactions Affecting Antiarrhythmic Drug Use. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2022, 15, 101161CIRCEP121007955.	2.1	6
216	Implantable Cardioverter Defibrillator Practices and Costs at an Academic Medical Center. <i>Journal of Cardiovascular Electrophysiology</i> , 2001, 12, 162-166.	0.8	5

#	ARTICLE	IF	CITATIONS
217	Older Persons with Diabetes Receive Fewer Inappropriate ICD Shocks: Results from the INTRINSIC RV Trial. <i>Journal of Cardiovascular Translational Research</i> , 2011, 4, 27-34.	1.1	5
218	Syncope in Patients with Organic Heart Disease. <i>Cardiology Clinics</i> , 2015, 33, 449-463.	0.9	5
219	Frailty and multi-morbidities should not govern oral anticoagulation therapy prescribing for patients with atrial fibrillation. <i>American Heart Journal</i> , 2019, 208, 120-122.	1.2	5
220	Pacing Therapies for Vasovagal Syncope. <i>Journal of Atrial Fibrillation</i> , 2020, 13, 2406.	0.5	5
221	Heart rate score and outcomes in ICD patients: insights from the prospective randomized INTRINSIC RV trial. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2022, 64, 87-93.	0.6	5
222	Reflex vagal control of atrial repolarization. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 1996, 271, H870-H875.	1.5	4
223	Amiodarone-Induced Pulmonary Toxicity. <i>New England Journal of Medicine</i> , 1997, 337, 1814-1814.	13.9	4
224	Autonomic influences in atrial ischemia: vagally mediated atrial conduction improvement. <i>International Journal of Cardiology</i> , 1997, 61, 157-163.	0.8	4
225	Predictive value of preoperative left ventricular ejection fraction and functional class for mortality and morbidity after high-risk coronary artery bypass grafting. <i>American Journal of Cardiology</i> , 2000, 85, 1489-1491.	0.7	4
226	For Whom Does the Bell Toll?. <i>Journal of Cardiovascular Electrophysiology</i> , 2001, 12, 1002-1003.	0.8	4
227	Advances in Atrial Flutter Mapping: What Goes Around Comes Around. <i>Journal of Cardiovascular Electrophysiology</i> , 2004, 15, 415-417.	0.8	4
228	Thorough QT Study With Recommended and Supratherapeutic Doses of Tolterodine. <i>Clinical Pharmacology and Therapeutics</i> , 2008, 83, 231-232.	2.3	4
229	Ibutilide revisited: stronger and safer than ever. <i>Europace</i> , 2008, 11, 9-10.	0.7	4
230	Electrocardiographic imaging: Back to the drawing board?. <i>Heart Rhythm</i> , 2011, 8, 700-701.	0.3	4
231	Sudden Death Risk in Syncope: The Role of The Implantable Cardioverter Defibrillator. <i>Progress in Cardiovascular Diseases</i> , 2013, 55, 443-453.	1.6	4
232	Electrical Stimulation of the Vagus Nerve for Chronic Heart Failure: Is It Time to Pull the Plug?. <i>Journal of Cardiac Failure</i> , 2016, 22, 643-645.	0.7	4
233	Conventional management of inappropriate sinus tachycardia. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2016, 46, 43-45.	0.6	4
234	Lower rate limit for pacing by cardiac resynchronization defibrillators: Should lower rate programming be reconsidered?. <i>Heart Rhythm</i> , 2021, 18, 2087-2093.	0.3	4

#	ARTICLE	IF	CITATIONS
235	Outcomes and predictors of readmission after implantation of a percutaneous left atrial appendage occlusion device in the United States: A propensity score-matched analysis from The National Readmission Database. <i>Journal of Cardiovascular Electrophysiology</i> , 2021, 32, 2961-2970.	0.8	4
236	Implantable Cardiac Monitors: Evolution Through Disruption. <i>Journal of Innovations in Cardiac Rhythm Management</i> , 2017, 8, 2824-2834.	0.2	4
237	Effect of Reproducibility of Baseline Arrhythmia Induction on Drug Efficacy Predictions and Outcome in the Electrophysiologic Study Versus Electrocardiographic Monitoring (ESVEM) Trial This study was supported in part by Grant RO-1-HL34071 from the National Heart, Lung, and Blood Institute, and Grant M01-RR00064 from the National Center for Research Resources, Bethesda, Maryland; and by Bristol-Myers Squibb Company, Princeton, New Jersey; Knoll Pharmaceutical Company, Whippany, New Jersey; Boehringer. <i>American Journal of Cardiology</i> , 1997, 80, 1448-1452.	0.7	3
238	Alternative medicine--boom or bust?. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2002, 6, 170-173.	0.9	3
239	Inadvertent Positioning of Pacemaker Leads in the Pericardium. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2003, 26, 2039-2041.	0.5	3
240	Cardioversion of atrial tachyarrhythmias: anticoagulation to reduce thromboembolic complications. <i>Progress in Cardiovascular Diseases</i> , 2004, 46, 487-505.	1.6	3
241	Is the approach to atrial fibrillation ablation becoming more complex and fractionated?. <i>Heart Rhythm</i> , 2006, 3, 35-36.	0.3	3
242	Fast-Track Training of Nonelectrophysiologists to Implant Defibrillators: Is It Needed?. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2006, 29, 627-631.	0.5	3
243	Treatment of PVCs post-myocardial infarction: Will we get fooled again?. <i>Heart Rhythm</i> , 2009, 6, 1550-1551.	0.3	3
244	The year in arrhythmias--2009: Part I. <i>Heart Rhythm</i> , 2010, 7, 417-426.	0.3	3
245	Response to Letter Regarding, "PR Interval Identifies Clinical Response in Patients With Non-Left Bundle Branch Block: A Multicenter Automatic Defibrillator Implantation Trial-Cardiac Resynchronization Therapy Sub-Study" by Kutuyifa et al. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2014, 7, 1280-1280.	2.1	3
246	Response. <i>Chest</i> , 2014, 145, 188-189.	0.4	3
247	Stroke Prophylaxis After a New Emergency Department Diagnosis of Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2018, 72, 471-472.	1.2	3
248	Electrolytes and the ECG Intervals. <i>Journal of the American College of Cardiology</i> , 2019, 73, 3132-3134.	1.2	3
249	Implantable Cardioverter Defibrillator Lead Survival in Athletic Patients. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2021, 14, e009344.	2.1	3
250	Resting sinus heart rate and first degree av block: modifiable risk predictors or epiphenomena?. <i>Indian Pacing and Electrophysiology Journal</i> , 2009, 9, 334-41.	0.3	3
251	Echocardiographic Assessment of Schizophrenics and Manics. <i>Journal of Nervous and Mental Disease</i> , 1985, 173, 179-181.	0.5	2
252	Pathological Study of an Explanted Heart Due to Intractable Ventricular Fibrillation. <i>Journal of Cardiovascular Electrophysiology</i> , 1992, 3, 437-441.	0.8	2

#	ARTICLE	IF	CITATIONS
253	Asymptomatic Nonsustained Ventricular Arrhythmias. Hospital Practice (1995), 1993, 28, 129-144.	0.5	2
254	A Practical Approach to Atrial Fibrillation. Hospital Practice (1995), 1999, 34, 61-78.	0.5	2
255	Radiofrequency application to the posteroseptal region alters retrograde accessory pathway activation. Journal of Interventional Cardiac Electrophysiology, 2000, 4, 283-293.	0.6	2
256	Acute anticoagulation adjustment in patients with atrial fibrillation at risk for stroke: approaches, strategies, risks and benefits. Expert Review of Cardiovascular Therapy, 2005, 3, 571-590.	0.6	2
257	Can lipid-lowering medication reduce the prevalence of atrial fibrillation in patients with left ventricular dysfunction?. Nature Clinical Practice Cardiovascular Medicine, 2007, 4, 16-17.	3.3	2
258	Antiarrhythmic Effects of Statins in Heart Failure. Heart Failure Clinics, 2008, 4, 187-200.	1.0	2
259	Carotid sinus hypersensitivity: disease state or clinical sign of ageing? The need for hard endpoints. Europace, 2010, 12, 1516-1517.	0.7	2
260	OptiVol Fluid Index: Does an Association With Ventricular Arrhythmias Hold Water?. Journal of Cardiovascular Electrophysiology, 2011, 22, 300-301.	0.8	2
261	Using omega-3 fatty acids to treat persistent atrial fibrillation: Time to fish or cut bait?. Heart Rhythm, 2012, 9, 492-493.	0.3	2
262	The Editor's Roundtable: Medical Management of Atrial Fibrillation. American Journal of Cardiology, 2012, 109, 563-569.	0.7	2
263	Syncope in Patients with Organic Heart Disease. Cardiac Electrophysiology Clinics, 2013, 5, 495-509.	0.7	2
264	Endovascular procedures for the treatment of autonomic dysfunction. Clinical Autonomic Research, 2014, 24, 1-2.	1.4	2
265	Automatic external defibrillator—only resuscitation in cardiac arrest? The approach may be shocking!. American Heart Journal, 2016, 172, 182-184.	1.2	2
266	Does First Degree AV Block Have Importance in Patients Considered for Cardiac Resynchronization Therapy?. JACC: Clinical Electrophysiology, 2017, 3, 827-829.	1.3	2
267	Short-Term Outcomes of Apixaban Versus Warfarin in Patients With Atrial Fibrillation. Circulation, 2019, 139, 2301-2303.	1.6	2
268	Editorial commentary: Vagal nerve stimulation for myocardial ischemia-reperfusion injury: Hope or Hype?. Trends in Cardiovascular Medicine, 2020, 30, 489-490.	2.3	2
269	The electrocardiogram: are we at the dawn of a new era?. European Heart Journal, 2020, 41, 2000-2002.	1.0	2
270	Is competitive atrial pacing a possible trigger for atrial fibrillation? Observations from the RATE registry. Heart Rhythm, 2021, 18, 3-9.	0.3	2

#	ARTICLE	IF	CITATIONS
271	Anticoagulant selection in relation to the SAME-TT2R2 score in patients with atrial fibrillation: The GLORIA-AF registry. <i>Hellenic Journal of Cardiology</i> , 2021, 62, 152-157.	0.4	2
272	Acute Water Ingestion as a Treatment for Postural Orthostatic Tachycardia Syndrome. <i>Journal of Innovations in Cardiac Rhythm Management</i> , 2019, 10, 3541-3544.	0.2	2
273	Toward a Common Definition of Syncope in Children and Adults. <i>Pediatric Emergency Care</i> , 2021, 37, e66-e67.	0.5	2
274	Association Between Atrial Fibrillation and Occupational Exposure in Firefighters Based on Self-Reported Survey Data. <i>Journal of the American Heart Association</i> , 2022, 11, e022543.	1.6	2
275	Surgical Ablation of Ventricular Tachycardia in the Normothermic Heart. <i>Journal of Cardiac Surgery</i> , 1990, 5, 115-121.	0.3	1
276	Various Electrocardiographic and Electrophysiologic Presentations of Normal and Abnormal Sinus Node. <i>Journal of Cardiovascular Electrophysiology</i> , 1992, 3, 187-197.	0.8	1
277	Efficacy and Adverse Effects of Moracizine for Ventricular Tachycardia. <i>Drug Investigation</i> , 1993, 6, 119-126.	0.6	1
278	Dofetilide Versus Quinidine for Atrial Flutter... <i>Journal of Cardiovascular Electrophysiology</i> , 1996, 7, 828-832.	0.8	1
279	Symptomatic Atrioventricular Block in an Atriofascicular Pathway Inserting into the Left Bundle Branch Without Apparent Atrioventricular Node Function. <i>Journal of Cardiovascular Electrophysiology</i> , 1997, 8, 922-926.	0.8	1
280	The Death of My Father. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2000, 23, 525-526.	0.5	1
281	Implantable cardioverter defibrillator therapy for patients with life-threatening ventricular arrhythmias and severe heart failure. <i>American Journal of Cardiology</i> , 2000, 86, 875-877.	0.7	1
282	Apparent bidirectional conduction block following radiofrequency catheter ablation of typical atrial flutter. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2001, 5, 109-118.	0.6	1
283	Unusual Response to Atrial Extrastimulus Testing. <i>Journal of Cardiovascular Electrophysiology</i> , 2002, 13, 200-200.	0.8	1
284	Rate versus rhythm control strategies for AF. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2005, 7, 371-381.	0.4	1
285	Electrophysiologists Prefer Dual-Chamber Implantable Cardioverter Defibrillator Programming Even When Right Ventricular Pacing Is Likely. <i>Journal of Cardiac Failure</i> , 2005, 11, S147.	0.7	1
286	Not so innocent bystander(s). <i>Europace</i> , 2009, 11, 1230-1234.	0.7	1
287	Prescription omega-3 fatty acids did not prevent recurrent, symptomatic, paroxysmal or persistent atrial fibrillation. <i>Annals of Internal Medicine</i> , 2011, 154, JC5.	2.0	1
288	The Editor's Roundtable: Implantable Cardioverter-Defibrillators in Primary Prevention of Sudden Cardiac Death and Disparity-Related Barriers to Implementation. <i>American Journal of Cardiology</i> , 2011, 107, 583-590.	0.7	1

#	ARTICLE	IF	CITATIONS
289	Factors affecting quality of warfarin anticoagulation in patients with atrial fibrillation: insights from affirm. <i>Heart</i> , 2012, 98, A32.2-A32.	1.2	1
290	Response. <i>Chest</i> , 2014, 145, 419-420.	0.4	1
291	Does change in device detected frequency of non-sustained or diverted episodes serve as a marker for inappropriate shock therapy? Analyses from the INTRINSIC RV and ALTITUDE-REDUCES Trials. <i>Europace</i> , 2014, 16, 668-673.	0.7	1
292	Warning: Acute pancreatitis is associated with slightly higher current amiodarone use. <i>Heart Rhythm</i> , 2015, 12, 167-168.	0.3	1
293	PREDICTORS OF ANTICOAGULANT PRESCRIPTION IN PATIENTS WITH ATRIAL FIBRILLATION IN NORTH AMERICA: THE GLORIA-AF REGISTRY. <i>Journal of the American College of Cardiology</i> , 2017, 69, 413.	1.2	1
294	Tachycardia-induced ventricular dysfunction jigsaw: do all pieces now fit?. <i>Acta Physiologica</i> , 2017, 219, 702-703.	1.8	1
295	Outcomes in syncope research: it is time to standardize. <i>Internal and Emergency Medicine</i> , 2018, 13, 589-591.	1.0	1
296	Disparities in atrial fibrillation management: Is race to blame?. <i>International Journal of Cardiology</i> , 2021, 331, 118-119.	0.8	1
297	Sinus node dysfunction - A well-defined entity?. <i>International Journal of Cardiology</i> , 2021, 335, 55-56.	0.8	1
298	Use of Electrophysiology Studies in Syncope: Practical Aspects for Diagnosis and Treatment. , 0, , 126-158.		1
299	Sympathetic influences on electrical and mechanical alternans in the canine heart. <i>Cardiovascular Research</i> , 1996, 32, 854-860.	1.8	1
300	Advances in the management of atrial fibrillation in congestive heart failure. <i>F1000 Medicine Reports</i> , 2009, 1, .	2.9	1
301	Electrophysiological Approach to Syncope and Near-Syncope in the Athlete. , 2011, , 181-212.		1
302	Syncope. <i>Cardiology Journal</i> , 2014, 21, 589-590.	0.5	1
303	The Parasympathetic Nervous System and Heart Failure: Pathophysiology and Potential Therapeutic Modalities for Heart Failure. , 2015, , 107-128.		1
304	A Case of Postablation Pericardial Effusion. <i>Journal of Innovations in Cardiac Rhythm Management</i> , 2018, 9, 3365-3368.	0.2	1
305	Evaluation and Management of Syncope: Comparing the Guidelines of the American College of Cardiology/American Heart Association/Heart Rhythm Society and the European Society of Cardiology. <i>Journal of Innovations in Cardiac Rhythm Management</i> , 2018, 9, 3457-3463.	0.2	1
306	Driving and Syncope. , 0, , 322-342.		1

#	ARTICLE	IF	CITATIONS
307	An Approach to Evaluative Research in Social Planning. <i>Social Service Review</i> , 1963, 37, 429-440.	0.3	0
308	Coronary Artery Bypass in Patients with Previously Placed Implantable Defibrillators. <i>PACE - Pacing and Clinical Electrophysiology</i> , 1993, 16, 2087-2091.	0.5	0
309	Atrial flutter. <i>Current Treatment Options in Cardiovascular Medicine</i> , 1999, 1, 167-177.	0.4	0
310	Request for assistance. <i>American Journal of Cardiology</i> , 1999, 84, 1277.	0.7	0
311	Request for assistance. <i>American Journal of Cardiology</i> , 2000, 85, 674.	0.7	0
312	Request for assistance. <i>American Journal of Cardiology</i> , 2000, 85, 800.	0.7	0
313	Request for assistance. <i>American Journal of Cardiology</i> , 2000, 85, 1041.	0.7	0
314	Syncope. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2001, 3, 299-310.	0.4	0
315	Rate control in atrial fibrillation: what approach is best?. <i>Current Cardiology Reports</i> , 2004, 6, 351-353.	1.3	0
316	Optimization of right ventricular pacing among patients with dual-chamber implantable cardioverter defibrillators. <i>Journal of Cardiac Failure</i> , 2004, 10, S66.	0.7	0
317	Anticoagulation: New challenges, old drugs. <i>Current Cardiology Reports</i> , 2005, 7, 359-361.	1.3	0
318	The Association between Right Ventricular Pacing and Use of the AV Search Hysteresis Algorithm in Patients with Implantable Cardioverter Defibrillators: Analysis of a Large Population. <i>Journal of Cardiac Failure</i> , 2006, 12, S63.	0.7	0
319	Are We Overestimating Percentage of Right Ventricular Pacing in Patients with Implantable Cardioverter Defibrillators?. <i>Journal of Cardiac Failure</i> , 2006, 12, S68.	0.7	0
320	Risk Stratificationâ€™ Impact Diagnostic Strategy. , 0, , 24-28.		0
321	The Understudy: On Being a Doctor. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2008, 31, 1640-1640.	0.5	0
322	Electrophysiological device therapy (implantable defibrillators) in older adults. <i>Current Cardiovascular Risk Reports</i> , 2009, 3, 347-354.	0.8	0
323	Dronedronone: evidence supporting its therapeutic use in the treatment of atrial fibrillation. <i>Core Evidence</i> , 2010, 5, 49.	4.7	0
324	Response to Letters Regarding Article, â€œHeart Rate Predicts Outcomes in an Implantable Cardioverter-Defibrillator Populationâ€•. <i>Circulation</i> , 2010, 121, .	1.6	0

#	ARTICLE	IF	CITATIONS
325	In permanent atrial fibrillation, lenient rate control is not inferior to strict rate control for preventing cardiovascular morbidity and mortality. Evidence-Based Medicine, 2010, 15, 147-148.	0.6	0
326	The year in arrhythmias—2009 Part II. Heart Rhythm, 2010, 7, 538-548.	0.3	0
327	Is a Dual-Chamber ICD Always Better in Patients Requiring an ICD?. Cardiac Electrophysiology Clinics, 2011, 3, 577-592.	0.7	0
328	Left ventricular geometry and outcome in patients with atrial fibrillation: insights from the AFFIRM trial. Heart, 2012, 98, A32.3-A33.	1.2	0
329	The Road Ends in Detroit. PACE - Pacing and Clinical Electrophysiology, 2012, 35, 754-756.	0.5	0
330	Mode of death and factors associated with cardiac and non-cardiac death in the MADIT-RIT trial. European Heart Journal, 2013, 34, P1375-P1375.	1.0	0
331	Bundle Branch Reentry Tachycardia. , 2014, , 835-847.		0
332	Neither Too Fast Nor Too Hot. Journal of the American College of Cardiology, 2014, 64, 470-471.	1.2	0
333	An unusual ICD shock: What is the mechanism?. HeartRhythm Case Reports, 2015, 1, 498-502.	0.2	0
334	The non-vitamin K oral anticoagulants (NOACs): Have all questions been answered?. Trends in Cardiovascular Medicine, 2015, 25, 337-339.	2.3	0
335	On the Road Again After Vasovagal Syncope?. JACC: Clinical Electrophysiology, 2016, 2, 209-211.	1.3	0
336	MY APPROACH to the patient with supraventricular tachycardia. Trends in Cardiovascular Medicine, 2017, 27, 378-379.	2.3	0
337	Stroke Prophylaxis and 30-Day Clinical Outcomes After US Emergency Department Diagnosis and Discharge for Atrial Fibrillation. Annals of Emergency Medicine, 2017, 70, S43.	0.3	0
338	How to Perform Pacemaker Troubleshooting. , 2017, , 173-186.		0
339	Bundle Branch Reentry Tachycardia. , 2018, , 799-813.		0
340	82 The Impact of Stroke Prophylaxis on Clinical Outcomes After US Emergency Department Diagnosis and Discharge for Atrial Fibrillation. Annals of Emergency Medicine, 2018, 72, S36.	0.3	0
341	The Very Little Lady Who Wasn't So Little: Steve Olshansky,* "The Otter". PACE - Pacing and Clinical Electrophysiology, 2018, 41, 1268-1268.	0.5	0
342	Development of Cardiac Implantable Electrical Devices. , 2018, , 1-12.		0

#	ARTICLE	IF	CITATIONS
343	Canâ€™t get out of this world alive. Europace, 2019, 21, 995-996.	0.7	0
344	Heart rate score predicts mortality independent of shocks in ICD and CRT-D patients. Journal of Interventional Cardiac Electrophysiology, 2020, 58, 103-111.	0.6	0
345	TACH-ING AWAY: PERMANENT JUNCTIONAL RECIPROCATING TACHYCARDIA. Journal of the American College of Cardiology, 2020, 75, 3221.	1.2	0
346	Editorial commentary: The autonomic nervous system is our friend. Trends in Cardiovascular Medicine, 2021, 31, 303-304.	2.3	0
347	Marijuana use disorder and arrhythmias: what were they smoking?. Europace, 2021, 23, 1155-1156.	0.7	0
348	Indications for Implantable Cardioverter Defibrillators. , 2008, , 495-546.		0
349	Diagnosis of Arrhythmias with Non-invasive Tools. , 2011, , 89-122.		0
350	Highlights from Heart Rhythm 2018: Late-breaking Clinical Trial Considerations. Journal of Innovations in Cardiac Rhythm Management, 2018, 10, 3321-3323.	0.2	0
351	The Mysterious Case of an Athletic Woman with Recurrent Syncope and a â€œNormalâ€•Heart. Journal of Innovations in Cardiac Rhythm Management, 2019, 10, 3744-3749.	0.2	0
352	Device Autonomic Regulation Therapy in Patients with Heart Failure and Reduced Ejection Fraction. Journal of Atrial Fibrillation, 2020, 13, 2409.	0.5	0
353	Syncope: Definition and Classification-Contrasting the American and European Guidelines. , 2020, , 3-16.		0
354	A 63-Year-Old Man with Atrial Fibrillation and Syncope. , 2020, , 67-68.		0
355	REDUCE-IT: accumulation of data across prespecified interim analyses to final results. European Heart Journal, 2020, 41, .	1.0	0
356	Abstract 14500: Physical Activity in Individuals With the Long Qt Syndrome: Baseline Data From the Lifestyle and Exercise in Long Qt Study (live Lqts). Circulation, 2020, 142, .	1.6	0
357	Anthracycline-induced cardiomyopathy: Is there a new light at the end of the tunnel?. Heart Rhythm O2, 2021, 2, 742-743.	0.6	0
358	Inherited Arrhythmic and Related Causes of Syncope. , 0, , 207-213.		0
359	Syncope and the Implantable Cardioverter Defibrillator. , 0, , 169-186.		0
360	Arrhythmia-Induced Cardiomyopathy: Mechanisms and Risk Assessment to Guide Management and Follow-Up. Current Cardiovascular Risk Reports, 0, , .	0.8	0